Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte

Leukemia & Lymphoma
C GisselbrechtF Reyes

Abstract

The purpose of this study was to, assess the efficacy of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in the prevention of neutropenia and infection in patients receiving dose-intensive chemotherapy for non-Hodgkin's lymphoma (NHL). A second objective was to determine clinical predicators of delay to cytotoxic chemotherapy administration. One hundred-sixty two patients with intermediate- or high-grade NHL and at least one poor prognostic factor received a total of 4 cycles of the LNH-84-regimen every 2 weeks, with an open randomization to treatment with anthracyclines. Patients were randomized to receive subcutaneous lenograstim 5 micrograms/kg/day (n = 82) or placebo (n = 80) from day 6 to day 13 of each cycle. The incidence of severe neutropenia (absolute neutrophil count (ANC) < 0.5 x 10(9)/L) was reduced in the lenograstim group compared with placebo (52% vs 75%). A significant reduction (p < 0.001) in the median duration of ANC < 0.5 x 10(9)/L was also observed in patients treated with lenograstim during each cycle of chemotherapy (0-1 day vs 2-4 days in placebo recipients). Fever occurred in 66 patients in each treatment group. Thirty-four percent of placebo recipients had documented ...Continue Reading

References

Jan 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR I Fisher
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A TalcottL Goldman
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B CoiffierN Brousse
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B ChevallierC Fizames
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project

❮ Previous
Next ❯

Citations

Nov 1, 2011·Journal of the National Cancer Institute·Arnold L PotoskyJane C Weeks
Jan 9, 2003·Expert Opinion on Biological Therapy·Fenella Willis, Ruth Pettengell
Sep 27, 2003·British Journal of Haematology·Antonio PagliucaUNKNOWN Haemato-Oncology Task Force of the British Committee for Standards in Haematology
Mar 31, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Li WangRichard Barron
Sep 15, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jason MadanRon Akehurst
Sep 18, 2016·Journal of the American Medical Informatics Association : JAMIA·Pamala A PawloskiGary H Lyman
Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·J E VisvaderG J Lindeman
Feb 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseB C Liang
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Mar 7, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kelvin K W ChanShabbir M H Alibhai
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C PatteJ Michon
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Jul 17, 2008·Supportive Cancer Therapy·Gary H Lyman, Nicole M Kuderer
Sep 12, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Hassam BaigPhuong K Morrow
Oct 16, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Magali Laprise-LachanceJean-Pierre Grégoire
Dec 30, 2014·BMC Systems Biology·Sibylle SchirmMarkus Scholz
May 1, 2012·PharmacoEconomics·Bradford R Hirsch, Gary H Lyman
Feb 19, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lee S SchwartzbergEsteban Abella
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E JohnstonG Schwab
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Mar 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H TillyB Coiffier
Dec 4, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Gary H LymanLodovico Balducci
Dec 22, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MorelUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.